Results 51 to 60 of about 4,832 (178)

Effectiveness of Switching to Benralizumab in Severe Refractory Eosinophilic Asthma

, 2022
PURPOSE: Benralizumab is a monoclonal antibody that targets the α subunit of the IL-5 receptor. Clinical trials have demonstrated the efficacy of this agent with respect to lung function and symptom control in patients with refractory eosinophilic asthma.
Medina Gallardo, Juan Francisco, Gallego Borrego, Javier, Gómez-Bastero Fernández, Ana, Álvarez-Gutiérrez, Francisco Javier, Delgado Romero, Julio, Romero Falcón, Auxiliadora, Benito Bernáldez, Cristina   +6 more
core   +1 more source

Transcriptomics reveals new regulatory mechanisms involved in benralizumab response [PDF]

, 2023
[EN] Benralizumab, a monoclonal antibody targeting IL5RA, significantly improves asthma symptoms and quality of life in severe asthmatic patients. However, understanding the factors influencing treatment response remains a challenge.
Gómez‐García, Manuel, Pérez Pazos, Jacqueline, Ramos González, Jacinto, Dávila González, Ignacio Jesús, Muñoz Bellido, Francisco Javier, Moreno‐Jimenez, Emma, Martín García, Cristina, Triviño, Juan Carlos, Gil Melcón, María, Isidoro García, María, García Sánchez, María Asunción, Morgado, Natalia, Estravís Sastre, Miguel, Sanz Lozano, Catalina Sofía   +13 more
core   +1 more source

Real-life effects of benralizumab on airway oscillometry in severe eosinophilic asthma

BMJ Open Respiratory Research, 2023
Introduction Eosinophil depletion with benralizumab reduces exacerbations and improves disease control and FEV1 in patients with severe eosinophilic asthma. However, few studies have investigated the effect of biologics on small airways dysfunction (SAD)
Brian J Lipworth, Rory Chan
doaj   +1 more source

Benralizumab: Cibler le récepteur de l'IL-5 dans l'asthme sévère éosinophile

, 2019
Benralizumab: Targeting the IL-5 Receptor in Severe Eosinophilic Asthma Abstract:For patients with difficult-to-control, severe bronchial asthma, highly effective, targeted treatment options are available in addition to inhaled medication.
Thomas Rothe, Solèr, Markus, Schmid-Grendelmeier, Peter, Peter Schmid-Grendelmeier, Gunther Pendl, von Garnier, Christophe, Simon, Hans-Uwe, Christophe von Garnier, Hans-Uwe Simon, Claudio Schuoler, Jörg D. Leuppi, Rothe, Thomas, Pendl, Gunther, Markus Solèr, Leuppi, Jörg D, Schuoler, Claudio   +15 more
core   +1 more source

Benralizumab use in chronic eosinophilic pneumonia with eosinophilic bronchiolitis and chronic airway infection

Respirology Case Reports, 2021
Chronic eosinophilic pneumonia (CEP) is a rare disorder characterized by marked accumulation of eosinophils in lung tissues and/or bronchoalveolar lavage fluid (BALF). Patients with CEP usually respond well to corticosteroids.
Tomotsugu Takano, Yuh Inutsuka, Satoshi Nakamura, Nobuhisa Ando, Masashi Komori   +4 more
doaj   +1 more source

Effectiveness and safety of anti-IL-5/Rα biologics in eosinophilic granulomatosis with polyangiitis: a two-year multicenter observational study

Frontiers in Immunology, 2023
BackgroundEosinophilic granulomatosis with polyangiitis (EGPA) is a rare vasculitis characterized by asthma, systemic manifestations, and blood and tissue eosinophilia.ObjectiveTo assess the effectiveness and safety of mepolizumab (anti-IL-5) and ...
Santi Nolasco, Santi Nolasco, Andrea Portacci, Raffaele Campisi, Enrico Buonamico, Corrado Pelaia, Alida Benfante, Massimo Triggiani, Giuseppe Spadaro, Maria Filomena Caiaffa, Giulia Scioscia, Aikaterini Detoraki, Giuseppe Valenti, Francesco Papia, Alessandra Tomasello, Nunzio Crimi, Nicola Scichilone, Girolamo Pelaia, Giovanna Elisiana Carpagnano, Claudia Crimi, Claudia Crimi   +20 more
doaj   +1 more source

Rapid Effect of Benralizumab for Hypereosinophilia in a Case of Severe Asthma with Eosinophilic Chronic Rhinosinusitis

Medicina, 2019
A 56-year-old man with severe asthma underwent bronchial thermoplasty (BT). However, his asthma exacerbated and hypereosinophilia developed 2 months later, thus necessitating oral corticosteroid (OCS) therapy.
Hiroaki Tsurumaki, Toshiyuki Matsuyama, Kazuma Ezawa, Yasuhiko Koga, Masakiyo Yatomi, Haruka Aoki-Saito, Kazuaki Chikamatsu, Takeshi Hisada   +7 more
doaj   +1 more source

Evaluating the Potential Infectious Risk Profile of Biologics in Chronic Rhinosinusitis With Nasal Polyposis

International Forum of Allergy &Rhinology, EarlyView.
Maxime Fieux, Philippe Gevaert, Leigh J. Sowerby   +2 more
wiley   +1 more source

A Real‐World Controlled Multicentre Study Evaluating the Association Between Benralizumab Therapy and Major Outcomes in Severe Asthma

Clinical &Experimental Allergy, EarlyView.
Among patients with severe eosinophilic asthma, benralizumab was associated with greater improvements in asthma outcomes—such as improved asthma control, quality of life and remission rates—compared to biologic‐naïve patients. ABSTRACT Background Real‐world data on benralizumab in patients with severe eosinophilic asthma–while controlling for ...
Dennis Thomas, Vanessa M. McDonald, Gijo Thomas, Joy Lee, Li Ping Chung, Matthew Peters, Shakti D. Shukla, Yuto Hamada, Erin S. Harvey, Michael Fricker, Hayley See, Rejoy Sabin Thomas, Claude S. Farah, Andrew Gillman, Constance H. Katelaris, Gregory P. Katsoulotos, David Langton, Peter G. Middleton, Paul Reynolds, Janet Rimmer, Francis Thien, Stephen Vincent, John W. Upham, Peter G. Gibson   +23 more
wiley   +1 more source

Impact of Biologics on Oscillometry Defined Small Airway Dysfunction in Uncontrolled Asthma

Clinical &Experimental Allergy, EarlyView.
Forced oscillometry technique defined small airways dysfunction as a treatable trait in asthma. Monoclonal antibodies can improve small airways dysfunction, but their effects vary by mechanism of action. ABSTRACT Small airways dysfunction (SAD) is a recognised treatable trait within severe asthma, associated with worse symptom control and increased ...
Robert Greig, Philipp Suter, Rory Chan, Brian Lipworth   +3 more
wiley   +1 more source